Dynavax Technologies (NASDAQ:DVAX) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Dynavax Technologies (NASDAQ:DVAX - Free Report) in a report released on Friday morning,Benzinga reports. The firm currently has a $31.00 price objective on the biopharmaceutical company's stock. HC Wainwright also issued estimates for Dynavax Technologies' FY2026 earnings at $0.54 EPS and FY2027 earnings at $0.69 EPS.

Several other equities analysts have also weighed in on the stock. The Goldman Sachs Group lowered shares of Dynavax Technologies from a "neutral" rating to a "sell" rating and reduced their target price for the company from $15.00 to $12.00 in a report on Tuesday, February 11th. StockNews.com cut Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Wednesday, February 12th.

Dynavax Technologies Trading Down 0.1 %

DVAX stock traded down $0.01 during trading on Friday, reaching $13.41. 1,783,038 shares of the stock traded hands, compared to its average volume of 1,834,979. The firm has a market capitalization of $1.76 billion, a PE ratio of 74.50 and a beta of 1.32. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The business's 50 day moving average price is $12.83 and its 200-day moving average price is $12.06. Dynavax Technologies has a 52-week low of $9.74 and a 52-week high of $14.05.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.05. The firm had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. As a group, sell-side analysts forecast that Dynavax Technologies will post 0.32 earnings per share for the current year.

Institutional Investors Weigh In On Dynavax Technologies

A number of large investors have recently added to or reduced their stakes in the company. US Bancorp DE boosted its position in Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 2,034 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 1,169 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in Dynavax Technologies by 463.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 2,034 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Dynavax Technologies during the 4th quarter worth approximately $35,000. Finally, Capital Performance Advisors LLP acquired a new position in shares of Dynavax Technologies in the 3rd quarter valued at approximately $45,000. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.